Sanofi $SNY Stock Sold by ProVise Management Group LLC

ProVise Management Group LLC lessened its stake in shares of Sanofi (NASDAQ:SNY) by 74.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 30,980 shares of the company’s stock after selling 89,849 shares during the period. ProVise Management Group LLC’s holdings in Sanofi were worth $1,277,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Moors & Cabot Inc. raised its position in shares of Sanofi by 4.4% during the third quarter. Moors & Cabot Inc. now owns 10,497 shares of the company’s stock worth $433,000 after purchasing an additional 446 shares during the period. Allworth Financial LP boosted its position in shares of Sanofi by 4.7% in the 3rd quarter. Allworth Financial LP now owns 9,666 shares of the company’s stock valued at $412,000 after purchasing an additional 433 shares during the period. Fifth Third Bancorp boosted its position in shares of Sanofi by 28.3% in the 3rd quarter. Fifth Third Bancorp now owns 27,533 shares of the company’s stock valued at $1,135,000 after purchasing an additional 6,072 shares during the period. Ritholtz Wealth Management boosted its position in shares of Sanofi by 48.3% in the 3rd quarter. Ritholtz Wealth Management now owns 45,685 shares of the company’s stock valued at $1,884,000 after purchasing an additional 14,880 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Sanofi in the 3rd quarter valued at $3,715,000. 14.03% of the stock is owned by institutional investors.

Sanofi Stock Down 0.2%

Shares of Sanofi stock traded down $0.09 during midday trading on Friday, hitting $48.37. The company’s stock had a trading volume of 1,675,700 shares, compared to its average volume of 4,657,690. The firm has a market capitalization of $117.27 billion, a P/E ratio of 23.95, a PEG ratio of 1.33 and a beta of 0.31. The stock has a 50-day simple moving average of $42.68 and a 200-day simple moving average of $44.38. The company has a quick ratio of 0.27, a current ratio of 1.12 and a debt-to-equity ratio of 0.20. Sanofi has a 1-year low of $39.07 and a 1-year high of $52.67.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 30th. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.56 by $0.48. The business had revenue of $17.25 billion for the quarter, compared to the consensus estimate of $14.30 billion. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. Sanofi’s revenue for the quarter was up 16.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.91 earnings per share. As a group, sell-side analysts expect that Sanofi will post 5.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Royal Bank Of Canada began coverage on Sanofi in a research note on Tuesday, September 8th. They issued a “sector perform” rating on the stock. Berenberg Bank reaffirmed a “buy” rating on shares of Sanofi in a research note on Monday, October 5th. Weiss Ratings upgraded shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, November 2nd. DZ Bank reiterated a “buy” rating on shares of Sanofi in a report on Friday, July 31st. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $53.00.

About Sanofi

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.